Small bowel bleeding in patients with left ventricular assist device: outcomes of conservative therapy versus balloon-assisted enteroscopy

Badr Al-Bawardy¹, Sarah D. Schettle⁶, Emmanuel Gorospe⁶, Louis M. Wong Kee Song⁶, Naveen L. Pereira⁶, Jeffrey A. Alexander⁶, David H. Bruining⁶, Nayantara Coelho-Prabhu⁵, Jeff L. Fidler⁷, William J. Mauermann⁵, David W. Barbara⁵, Ross Dierkhising⁵, Elizabeth Rajan⁵

Mayo Clinic, Rochester, MN, USA

Abstract

Background Small bowel bleeding (SBB) accounts for 30% of gastrointestinal bleeding (GIB) episodes in patients with a left ventricular assist device (LVAD). The aim of this study was to determine the outcomes of conservative therapy (CT) compared to balloon-assisted enteroscopy (BAE) in the management of SBB in LVAD patients.

Methods A retrospective review was performed of a prospectively maintained LVAD database from January 2003 to July 2015. LVAD patients with SBB were classified into a BAE group or a CT group according to whether they did or did not undergo BAE.

Results Forty-two patients (22 BAE, 20 CT) with mean age 66±9.3 years (79% male) were included. The yield of BAE was 64% without reported complications. Overt re-bleeding occurred in 40% of the BAE group compared to 22% of the CT group. The BAE group had a higher mean number of GIB hospitalizations per month compared to the CT group (0.07 vs. 0.03; incidence rate ratio [IRR] 2.72, 95% CI 1.06-6.98; P=0.04). There was no significant difference between the BAE and the CT groups in the number of packed red blood cell (pRBC) transfusions per month (0.42 vs. 0.18; IRR 2.31, 95% CI 0.88-6.04; P=0.09) or all-cause mortality (61% in the CT group and 42% in the BAE group; P=0.90).

Conclusion BAE is safe in LVAD patients and has a moderate therapeutic yield. In our cohort of patients, BAE did not appear to improve re-bleeding rate, GIB-related hospitalizations, pRBC transfusions or mortality compared to CT. However, future prospective trials with larger sample sizes are needed to confirm these findings.

Keywords Small bowel bleeding, left ventricular assist device, capsule endoscopy, balloon-assisted enteroscopy

Ann Gastroenterol 2018; 31 (6): 692-697

Introduction

Left ventricular assist device (LVAD) therapy has been shown to improve survival and quality of life in advanced heart failure compared to medical therapy [1]. Both continuous (HeartMate II, Thoratec, Pleasanton, CA; HeartWare, Framingham, MA) and pulsatile flow (HeartMate III, HeartMate XVE, Thoratec, Pleasanton, CA) LVADs have been associated with an increased risk of gastrointestinal bleeding (GIB), higher for continuous-flow devices [2-4]. Multiple factors have been postulated that may increase the risk of GIB, including low pulsatility, pharmaceutical anticoagulation and acquired von Willebrand factor disease [5-8].

The reported prevalence of GIB in LVAD patients ranges from 16-23% [9-11]. In a recent meta-analysis, small bowel bleeding (SBB) accounted for 15% of GIB events in LVAD
Entero
cassations, and packed red blood cell (pRBC) transfusions per month were compared to account for the potential correlation between periods. The number of GIB hospitalizations and pRBC transfusions per month after the initial small bowel evaluation were compared between the BAE and CT groups using Poisson regression. Incidence rate ratios (IRRs) with 95% confidence intervals (CI) were computed from the Poisson models to compare incidence rates. The incidence of having a BAE after the initial small bowel evaluation in the BAE group was estimated using Kaplan-Meier methodology with adjustment for the competing risk of death.

Results

A total of 322 LVAD patients were reviewed. From this cohort, 97 patients (30%) had GIB post LVAD placement. Forty-two patients met the inclusion criteria (Fig. 1).

Baseline characteristics

The mean age (± standard deviation [SD]) was 66±9.3 years and 33 patients (79%) were male. A total of 22 patients underwent BAE and were classified in the BAE group while 20 patients underwent conservative management and were classified in the CT group. There was no statistically significant difference between the groups in terms of age, sex, etiology of heart failure, use of LVAD as destination therapy and chronic kidney disease requiring hemodialysis (Table 1). LVAD as destination therapy was employed in 71% of the study cohort. The proportion of patients who had HeartMate II implantation was 80% in the CT group and 91% in the BAE group (P=0.31). The median follow-up time after small bowel evaluation was 38 months and 28 months in the CT and BAE groups, respectively.

Overt GIB was observed in 65% of the CT group and 59% of the BAE group (P=0.69). Among the 26 overt GIB patients, the most common presentation was melena (85% in the BAE vs. 69% in the CT group; P=0.35). The mean time from LVAD implantation to first GIB was 241±369 days and 154±216 days (P=0.91) in the CT and BAE groups, respectively. There was no significant difference between the groups in the history of GIB pre-LVAD implantation (Table 1).

At the time of small bowel evaluation, the mean hemoglobin (9.2±1.0 g/dL vs. 9.4±1.1 g/dL; P=0.60) and international normalized ratio (INR) (1.5±0.8 vs. 1.2±0.3; P=0.08) levels were similar between the CT and BAE groups, respectively. The mean platelet count was 260±122 in the CT group and 171±54 (x 1000/µL) in the BAE group (P=0.004).

The BAE group was less likely to be on aspirin (68% vs. 95%; P=0.03) or warfarin (82% vs. 100%; P=0.05). There was no significant difference between the CT and BAE groups in the use of clopidogrel (10% vs. 14%; P=0.72). Among the 40 patients taking antithrombotic medication, the rate of de-escalation was similar in the CT and BAE groups (65% vs. 75%; P=0.49). A total of 8 patients (36%) in the BAE group and 1 patient (5%) in the CT group were on medical therapy for GIB. In the BAE group 7 patients were on danazol and 1 patient was on octreotide, while one patient in the CT group was on octreotide. In the BAE group 7 patients were on danazol and one patient (5%) in the CT group were on medical therapy for GIB.

Baseline comparisons between the CT and BAE groups were made using Wilcoxon rank-sum tests for continuous variables and Pearson's Chi-square tests for discrete variables. Death after the initial small bowel evaluation was compared between groups using Kaplan-Meier methodology and the log-rank test. The periods before and after the initial small bowel evaluation for the number of GIB hospitalizations and packed red blood cell (pRBC) transfusions per month were compared using Poisson regression with generalized estimating equations to account for the potential correlation between periods. The number of GIB hospitalizations and pRBC transfusions per month after the initial small bowel evaluation were compared between the BAE and CT groups using Poisson regression. Incidence rate ratios (IRRs) with 95% confidence intervals (CI) were computed from the Poisson models to compare incidence rates. The incidence of having a BAE after the initial small bowel evaluation in the BAE group was estimated using Kaplan-Meier methodology with adjustment for the competing risk of death.

Patients and methods

We conducted a retrospective review of a prospectively maintained LVAD database from January 2003 to July 2015. The study was approved by the Institutional Review Board. Patients with GIB after LVAD implantation were identified. SBB was defined as GIB in patients with normal upper endoscopy and colonoscopy. The study included patients who had overt or occult SBB and underwent BAE, or capsule endoscopy (CE) or computed tomography enterography (CTE). Overt GIB was defined as melena or hematochezia and occult GIB was defined as iron deficiency anemia and positive fecal occult blood.

Patients who met the inclusion criteria were classified into two groups. The CT group included patients who had SBB treated with either oral or parenteral iron replacement and/or blood transfusions. These patients had a CE and/or CTE performed but did not undergo BAE. The BAE group included all LVAD patients who had SBB treated with either oral or parenteral iron replacement and/or blood transfusions and underwent BAE. Patients in both the CT and BAE groups who received medical therapy for GIB, such as octreotide or danazol, at the discretion of the primary clinician were identified. The decision for patients to undergo BAE was made by the primary clinician. Balloon-assisted enteroscopy was performed with either single-balloon (SIF-Q180, Olympus Corp., Center Valley, Pennsylvania, USA) or double-balloon (EN-450T5, Fujinon, Inc., Saitama, Japan) enteroscopes. The decision to use a single versus a double balloon and an antegrade or retrograde approach was guided by the presumed location of the culprit lesion, detected by small bowel diagnostic imaging when available. Actively bleeding and any potential bleeding sites (such as non-bleeding angioectasia) were treated endoscopically during BAE. Re-bleeding was defined as recurrence of overt bleeding after initial BAE or after small bowel diagnostic imaging.

Baseline comparisons between the CT and BAE groups were made using Wilcoxon rank-sum tests for continuous variables and Pearson's Chi-square tests for discrete variables. Death after the initial small bowel evaluation was compared between groups using Kaplan-Meier methodology and the log-rank test. The periods before and after the initial small bowel evaluation for the number of GIB hospitalizations and packed red blood cell (pRBC) transfusions per month were compared using Poisson regression with generalized estimating equations to account for the potential correlation between periods. The number of GIB hospitalizations and pRBC transfusions per month after the initial small bowel evaluation were compared between the BAE and CT groups using Poisson regression. Incidence rate ratios (IRRs) with 95% confidence intervals (CI) were computed from the Poisson models to compare incidence rates. The incidence of having a BAE after the initial small bowel evaluation in the BAE group was estimated using Kaplan-Meier methodology with adjustment for the competing risk of death.

Results

A total of 322 LVAD patients were reviewed. From this cohort, 97 patients (30%) had GIB post LVAD placement. Forty-two patients met the inclusion criteria (Fig. 1).

Baseline characteristics

The mean age (± standard deviation [SD]) was 66±9.3 years and 33 patients (79%) were male. A total of 22 patients underwent BAE and were classified in the BAE group while 20 patients underwent conservative management and were classified in the CT group. There was no statistically significant difference between the groups in terms of age, sex, etiology of heart failure, use of LVAD as destination therapy and chronic kidney disease requiring hemodialysis (Table 1). LVAD as destination therapy was employed in 71% of the study cohort. The proportion of patients who had HeartMate II implantation was 80% in the CT group and 91% in the BAE group (P=0.31). The median follow-up time after small bowel evaluation was 38 months and 28 months in the CT and BAE groups, respectively.

Overt GIB was observed in 65% of the CT group and 59% of the BAE group (P=0.69). Among the 26 overt GIB patients, the most common presentation was melena (85% in the BAE vs. 69% in the CT group; P=0.35). The mean time from LVAD implantation to first GIB was 241±369 days and 154±216 days (P=0.91) in the CT and BAE groups, respectively. There was no significant difference between the groups in the history of GIB pre-LVAD implantation (Table 1).

At the time of small bowel evaluation, the mean hemoglobin (9.2±1.0 g/dL vs. 9.4±1.1 g/dL; P=0.60) and international normalized ratio (INR) (1.5±0.8 vs. 1.2±0.3; P=0.08) levels were similar between the CT and BAE groups, respectively. The mean platelet count was 260±122 in the CT group and 171±54 (x 1000/µL) in the BAE group (P=0.004).

The BAE group was less likely to be on aspirin (68% vs. 95%; P=0.03) or warfarin (82% vs. 100%; P=0.05). There was no significant difference between the CT and BAE groups in the use of clopidogrel (10% vs. 14%; P=0.72). Among the 40 patients taking antithrombotic medication, the rate of de-escalation was similar in the CT and BAE groups (65% vs. 75%; P=0.49). A total of 8 patients (36%) in the BAE group and 1 patient (5%) in the CT group were on medical therapy for GIB. In the BAE group 7 patients were on danazol and 1 patient was on octreotide, while one patient in the CT group was on octreotide. In the BAE group 7 patients were on danazol and one patient (5%) in the CT group were on medical therapy for GIB.
was on danazol. These therapies were initiated after SBB was confirmed with CE or CTE.

CE was positive in 67% (n=12) and 93% (n=14) of the CT and BAE groups, respectively (P=0.12) with visible blood and angioectasia being the most common findings. In the BAE group, one patient had a false negative CE with angioectasia found on BAE. There were no reported adverse events relating to the performance of CE in LVAD patients. A total of 6 patients had both CE and CTE. Small bowel evaluation modalities and findings are summarized in Table 2.

---

### Table 1 Baseline characteristics of LVAD patients with small bowel bleeding

| Characteristics                                      | CT (N=20) | BAE (N=22) | Total (N=42) | P-value |
|------------------------------------------------------|-----------|------------|--------------|---------|
| Age, mean (SD)                                       | 63.7 (10.2)| 68.6 (7.9) | 66.3 (9.3)   | 0.09    |
| Male, n (%)                                          | 15 (75.0) | 18 (81.8)  | 33 (78.6)    | 0.59    |
| Etiology of heart failure, n (%)                     | 12 (60.0) | 11 (50.0)  | 23 (54.8)    | 0.60    |
| Ischemic                                             |           |            |              |         |
| Dilated                                              | 7 (35.0)  | 8 (36.4)   | 15 (35.7)    |         |
| Other                                                | 1 (5.0)   | 3 (13.6)   | 4 (9.5)      |         |
| Type of LVAD, n (%)                                  |           |            |              | 0.31    |
| HeartMate II                                         | 16 (80.0) | 20 (90.9)  | 36 (85.7)    |         |
| HeartWare                                            | 4 (20.0)  | 2 (9.1)    | 6 (14.3)     |         |
| LVAD as destination therapy, n (%)                   | 15 (75.0) | 15 (68.2)  | 30 (71.4)    | 0.63    |
| History of GIB prior to LVAD, n (%)                  | 3 (15.0)  | 6 (27.3)   | 9 (21.4)     | 0.33    |
| Hemodialysis, n (%)                                  | 1 (5.0)   | 3 (13.6)   | 4 (9.5)      | 0.34    |

**BAE, balloon-assisted enteroscopy; CT, conservative therapy; SD, standard deviation; GIB, gastrointestinal bleeding; LVAD, left ventricular assist device**
The diagnostic and therapeutic yields of BAE were both 64%. The most common finding was angioectasia (64%). Thermal therapy was utilized in the majority of patients (64%). There were no adverse events related to BAE procedures. The likelihood of having a repeat BAE was 35% at 1 year and 43% at 3 years after the initial BAE. Balloon-assisted enteroscopy procedure details and findings are summarized in Table 3.

In the BAE group, the number of GIB-related hospitalizations per month decreased by 77% (IRR 0.23, 95%CI 0.11-0.50; P<0.001) after the initial BAE. The number of pRBC transfusions per month decreased by 82% (IRR 0.18, 95%CI 0.06-0.60; P=0.005) after the initial BAE.

CT vs. BAE outcomes

Overt re-bleeding occurred in 22% (median follow-up time of 38 months) in the CT group compared to 40% (median follow-up time of 28 months) in the BAE group. The BAE group had a significantly higher number of GIB-related hospitalizations per month compared to the CT group (0.07 vs. 0.03; IRR 2.72, 95%CI 1.06-6.98; P=0.04). The number of pRBC transfusions per month was 0.42 in the BAE group compared to 0.18 in the CT group (IRR 2.31, 95%CI 0.88-6.04; P=0.09). All-cause mortality was 61% in the CT group and 42% in the BAE group 36 months after the initial small bowel evaluation (P=0.90) (Fig. 2). There were no GIB-related deaths.

Discussion

In our cohort of LVAD patients with SBB, patients who underwent BAE did not have superior objective clinical outcomes in terms of GIB-related hospitalizations, number of pRBC transfusions, overt re-bleeding, or all-cause or GIB-related mortality compared to patients who underwent

---

**Table 2** Small bowel evaluation findings

| Evaluation modality        | CT (N=20)   | BAE (N=22) | Total (N=42) | P-value |
|----------------------------|-------------|------------|--------------|---------|
| Capsule endoscopy, n (%)   | 18 (90)     | 15 (68)    | 33 (79)      | 0.09    |
| Active bleeding            | 2 (11)      | 5 (33.3)   | 8 (24.2)     | 0.05    |
| Angioectasia               | 4 (22.2)    | 4 (26.7)   | 8 (24.2)     | 0.77    |
| Altered heme               | 5 (27.8)    | 5 (33.3)   | 12 (36.4)    | 0.69    |
| Ulceration                 | 1 (5.6)     | 0 (0.0)    | 4 (12.1)     | 0.38    |
| Gastric retention          | 1 (5.6)     | 0 (0.0)    | 1 (3.0)      | 0.35    |
| Negative                   | 5 (27.8)    | 1 (6.7)    | 6 (18.2)     | 0.12    |
| CTE, n (%)                 | 5 (25)      | 5 (22.7)   | 10 (24)      | 0.86    |
| Angioectasia               | 0 (0.0)     | 2 (40)     | 2 (20)       |         |
| Negative                   | 5 (100)     | 3 (60)     | 8 (80)       |         |

More than one evaluation modality and finding per patient is possible

*BAE, balloon-assisted enteroscopy; CT, conservative therapy; CTE, computed tomography enterography; LVAD, left ventricular assist device*

**Table 3** BAE findings

| Procedure details/findings | BAE n=22 |
|----------------------------|----------|
| Inpatient, n (%)           | 20 (91)  |
| Route of BAE, n (%)        |          |
| Antegrade                  | 12 (55)  |
| Retrograde                 | 10 (45)  |
| Findings, n (%)            |          |
| Actively bleeding angioectasia | 9 (41) |
| Non-bleeding angioectasia  | 5 (23)   |
| Negative                   | 6 (27)   |
| Unsuccessful exam          | 2 (9)    |
| Treatment modality, n (%)  |          |
| Thermal (APC or bipolar)   | 9 (64)   |
| Mechanical (hemoclip)       | 1 (7)    |
| Combination (mechanical + thermal) | 4 (29) |

*BAE, balloon-assisted enteroscopy; APC, argon plasma coagulation*

**Figure 2** Incidence of all-cause mortality in the BAE group and CT group

*BAE, balloon-assisted enteroscopy; CT, conservative therapy*
CT. We noted, however, that after the initial BAE, the number of GIB-related hospitalizations and pRBC transfusions per month improved in the BAE group. BAE was safe, without documented adverse events.

GIB is a known complication of LVAD therapy. The overall rate of GIB in our cohort was 30%, comparable to other published series [3,5,15]. Multiple pathophysiologic mechanisms have been proposed to account for the greater incidence of GIB in LVAD patients. Acquired von Willebrand disease is one key mechanism that has been described [5,16,17]. It has been well reported that continuous-flow devices are associated with a greater risk of GIB compared to pulsatile LVADs [2,3]. Increased intraluminal pressure, coupled with lower pulse pressure, leading to transient intestinal hypoperfusion appears to increase the risk of developing angioectasia in patients with continuous-flow LVADs [18].

Small bowel angioectasia treated by BAE carries a substantial risk of re-bleeding. In non-LVAD patients, multiple studies have shown the risk of re-bleeding after therapeutic BAE to be as high as 40–46% [19,20]. Our study showed similar results, with a re-bleeding rate of 40% following the initial BAE.

The safety and periprocedural management of LVAD patients undergoing upper endoscopy and colonoscopy has been well studied [21]. However, data regarding the safety and utility of BAE in this patient population are sparse. Edwards et al reported on the safety and findings of BAE in a small group of 10 LVAD patients with suspected SBB [13]. The diagnostic yield in that cohort was 39%, comparable to our diagnostic yield of 64% with no reported adverse events. The diagnostic yield of antegrade BAE is generally higher than that of retrograde BAE [22]. Kwong et al reviewed 28 cases of deep enteroscopy performed in LVAD patients and found no adverse events [23].

Our study appears to be the first to compare CT to BAE in LVAD patients with GIB; furthermore, although the sample size is small, it still represents the largest experience to date. This study is limited by its single-center nature and the inherent limitations of a retrospective study. Our study groups were similar in characteristics relevant to GIB, including age, INR, type of LVAD, and proportion of patients on destination therapy. Notably, while the BAE patients were less likely to be on aspirin and warfarin, they had more GIB-related hospitalizations and pRBC transfusions. Although the difference did not reach statistical significance, the CT group had a numerically higher all-cause mortality rate of 61%, compared to 42% in the BAE group. There was also a higher proportion of patients in the BAE group with a positive CE and more were on medical therapy (danazol and octreotide). Even though a history of GIB, active bleeding and chronic kidney disease requiring hemodialysis showed no statistically significant difference between the two groups, all were numerically more frequent in the BAE group, which may indicate more refractory or severe GIB compared to the CT group. Since these cumulative differences may potentially play a role in outcomes, additional studies with larger patient populations are needed to further support our findings. Another limitation of the study is physician referral bias, as patients referred for BAE may have been less stable; however, objective parameters such as mean hemoglobin, renal function, overt GIB and the use of antiplatelet/anticoagulation medication were not significantly different from those in the CT group.

In conclusion, BAE is safe in LVAD patients and has a moderate therapeutic yield. In our study population, performing BAE did not appear to reduce GIB-related hospitalizations, re-bleeding, pRBC transfusions or all-cause mortality compared to conservative management. However, future prospective trials with larger cohorts of patients are needed to confirm these findings.

References

1. Rose EA, Gelijns AC, Moskowitz AJ, et al; Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure (REMATCH) Study Group. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med 2001;345:1435-1443.
2. Crow S, John R, Boyle A, et al. Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices. J Thorac Cardiovasc Surg 2009;137:208-215.
3. Stern DR, Kazam J, Edwards P, et al. Increased incidence of gastrointestinal bleeding following implantation of the heartmate II LVAD. J Card Surg 2010;25:352-356.
4. Islam S, Cevik C, Madonna R, et al. Left ventricular assist devices and gastrointestinal bleeding: a narrative review of case reports and case series. Clin Cardiol 2013;36:190-200.
5. Uriel N, Pak SW, Jorde UP, et al. Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation. J Am Coll Cardiol 2010;56:1207-1213.

Summary Box

What is already known:

- The rate of small bowel bleeding (SBB) in left ventricular assist device (LVAD) patients can approach 31%
- Long-term outcomes of SBB in LVAD patients have not been widely studied
- The optimal management strategy for SBB (balloon-assisted enteroscopy [BAE] vs. conservative therapy [CT]) has not been clearly defined in LVAD patients

What the new findings are:

- BAE is safe in LVAD patients with SBB
- BAE has a moderate therapeutic yield in LVAD patients with SBB (64%)
- Compared to CT, BAE did not appear to improve long-term clinical outcomes, such as re-bleeding rate, hospitalizations, transfusion requirements, or mortality

Annals of Gastroenterology 31
6. Klovaite J, Gustafsson F, Mortensen SA, Sander K, Nielsen LB. Severely impaired von Willebrand factor-dependent platelet aggregation in patients with a continuous-flow left ventricular assist device (HeartMate II). *J Am Coll Cardiol* 2009;53:2162-2167.

7. Meyer AL, Malehsa D, Budde U, Bara C, Haverich A, Struemer M. Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. *JACC Heart Fail* 2014;2:141-145.

8. Wever-Pinzon O, Selzman CH, Drakos SG, et al. Pulsatility and the risk of nonsurgical bleeding in patients supported with the continuous-flow left ventricular assist device HeartMate II. *Circ* 2013;6:517-526.

9. Singh G, Albeledawi M, Kalra SS, Mehta PP, Lopez R, Vargo JJ. Features of patients with gastrointestinal bleeding after implantation of ventricular assist devices. *Clin Gastroenterol Hepatol* 2015;13:107-114.e101.

10. Shrode CW, Draper KV, Huang RJ, et al. Significantly higher rates of gastrointestinal bleeding and thromboembolic events with left ventricular assist devices. *Clin Gastroenterol Hepatol* 2014;12:1461-1467.

11. Draper KV, Huang RJ, Gerson LB. GI bleeding in patients with continuous-flow left ventricular assist devices: a systematic review and meta-analysis. *Gastrointest Endosc* 2014;80:435-446.e1.

12. Morgan JA, Paone G, Nemeh HW, et al. Gastrointestinal bleeding with the HeartMate II left ventricular assist device. *J Heart Lung Transplant* 2012;31:715-718.

13. Edwards AL, Mönkemüller K, Pamboukian SV, George JJ, Wilcox CM, Peter S. Utility of double-balloon enteroscopy in patients with left ventricular assist devices and obscure overt gastrointestinal bleeding. *Endoscopy* 2014;46:986-991.

14. Decker GA, Miller ED, Pasha SF, Harrison ME, Leighton JA. Deep enteroscopy in patients with left ventricular assist devices: practical and technical considerations. *Endoscopy* 2010;42(Suppl 2):E194.

15. Stulak JM, Lee D, Haft JW, et al. Gastrointestinal bleeding and subsequent risk of thromboembolic events during support with a left ventricular assist device. *J Heart Lung Transplant* 2014;33:60-64.

16. Geisen U, Heilmann C, Beyersdorf F, et al. Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. *Eur J Cardiothorac Surg* 2008;33:679-684.

17. Crow S, Chen D, Milano C, et al. Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. *Ann Thorac Surg* 2010;90:1263-1269.

18. Suarez J, Patel CB, Felker GM, et al. Mechanisms of bleeding and approach to patients with axial-flow left ventricular assist devices. *Circ* 2011;4:779-784.

19. Samaha E, Rahmi G, Landi B, et al. Long-term outcome of patients treated with double balloon enteroscopy for small bowel vascular lesions. *Am J Gastroenterol* 2012;107:240-246.

20. May A, Friesing-Sosnik T, Manner H, Pohl J, Ell C. Long-term outcome after argon plasma coagulation of small-bowel lesions using double-balloon enteroscopy in patients with mid-gastrointestinal bleeding. *Endoscopy* 2011;43:759-765.

21. Barbara DW, Olsen DA, Pulido JN, et al. Periprocedural management of 172 gastrointestinal endoscopies in patients with left ventricular assist devices. *ASAIO J* 2015;61:670-675.

22. Sanaka MR, Navaneethan U, Kosuru B, Yerneni H, Lopez R, Vargo JJ. Antegrade is more effective than retrograde enteroscopy for evaluation and management of suspected small-bowel disease. *Clin Gastroenterol Hepatol* 2012;10:910-916.

23. Kwong WT, Pearlman M, Kalmar D. Safety of deep enteroscopy and capsule endoscopy in LVAD patients: case report and literature review. *Gastroenterol Res* 2015;8:309-312.